Business Context and Reporting Period
Company: VistaGen Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 28, 2012
Event: Consummation of a private placement of convertible promissory notes and warrants to accredited investors.
Key Financial Metrics and Transaction Details
- Principal Amount Raised: $500,000 in convertible promissory notes.
- Interest Rate: 12% per annum, paid in kind quarterly.
- Maturity: 24 months from issuance or upon a "Qualified Financing" (gross proceeds of at least $4.0 million), whichever occurs first.
- Conversion Price: $3.00 per share for voluntary conversion.
- Automatic Conversion Trigger: Occurs upon a Qualified Financing if the price per unit/share is at least $2.00.
- Warrants Issued: Warrants to purchase 272,724 shares of Common Stock.
- Warrant Exercise Price: $2.75 per share.
- Warrant Term: 5 years from issuance.
- Use of Proceeds: General working capital purposes.
- Additional Financing Capacity: Company may issue up to an additional $2.5 million in similar notes.
Material Changes and Obligations
The filing reports the creation of a direct financial obligation. The Notes rank pari-passu with other promissory notes up to an aggregate principal amount of $3.0 million. The Company entered into a Registration Rights Agreement requiring the filing of a registration statement for the resale of Conversion Shares and Warrant Shares within 90 days of the closing date. Failure to file timely or achieve effectiveness may trigger penalty payments to purchasers.
Outlook, Risks, and Management Commentary
- Liquidity Risk: There is no assurance the Company will successfully place the additional $2.5 million in notes or secure other financing on acceptable terms.
- Dilution Risk: The transaction involves potential dilution through the conversion of notes and exercise of warrants.
- Regulatory Compliance: The securities were sold under Section 4(2) of the Securities Act and Rule 506 of Regulation D to accredited investors only.
- Management Statement: The transaction documents are not intended to provide comprehensive financial information about the Company's condition, and representations made therein may differ from standards applicable to general investors.
Investor Verification Checklist
- Verify the Company's current cash position and runway given the reliance on future financing for working capital.
- Confirm the status of the registration statement filing required within 90 days of February 28, 2012.
- Assess the likelihood of a "Qualified Financing" ($4.0 million) occurring within 24 months to trigger automatic conversion.
- Review the total outstanding debt to ensure the new $500,000 note does not exceed the $3.0 million aggregate limit for pari-passu notes.
- Monitor for any subsequent filings regarding the issuance of the additional $2.5 million in notes.